Activation of Benznidazole by Trypanosomal Type I Nitroreductases Results in Glyoxal Formation
- 1 January 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (1), 115-123
- https://doi.org/10.1128/aac.05135-11
Abstract
Benznidazole, a 2-nitroimidazole, is the front-line treatment used against American trypanosomiasis, a parasitic infection caused by Trypanosoma cruzi. Despite nearly 40 years of use, the trypanocidal activity of this prodrug is not fully understood. It has been proposed that benznidazole activation leads to the formation of reductive metabolites that can cause a series of deleterious effects, including DNA damage and thiol depletion. Here, we show that the key step in benznidazole activation involves an NADH-dependent trypanosomal type I nitroreductase. This catalyzes an oxygen-insensitive reaction with the interaction of enzyme, reductant, and prodrug occurring through a ping-pong mechanism. Liquid chromatography/mass spectrometry (LC/MS) analysis of the resultant metabolites identified 4,5-dihydro-4,5-dihydroxyimidazole as the major product of a reductive pathway proceeding through hydroxylamine and hydroxy intermediates. The breakdown of this product released the reactive dialdehyde glyoxal, which, in the presence of guanosine, generated guanosine-glyoxal adducts. These experiments indicate that the reduction of benznidazole by type I nitroreductase activity leads to the formation of highly reactive metabolites and that the expression of this enzyme is key to the trypanocidal properties displayed by the prodrug.Keywords
This publication has 54 references indexed in Scilit:
- Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile MetabolitesJournal of Biological Chemistry, 2011
- Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6Molecular and Biochemical Parasitology, 2011
- Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African TrypanosomiasisAntimicrobial Agents and Chemotherapy, 2010
- Exploiting the Drug-Activating Properties of a Novel Trypanosomal NitroreductaseAntimicrobial Agents and Chemotherapy, 2010
- Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and MetronidazoleJournal of Parasitology Research, 2009
- Characterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of Helicobacter pyloriThe FEBS Journal, 2009
- A comparative study of methylglyoxal metabolism in trypanosomatidsThe FEBS Journal, 2008
- A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomesProceedings of the National Academy of Sciences of the United States of America, 2008
- Deletion of the Trypanosoma brucei Superoxide Dismutase Gene sodb1 Increases Sensitivity to Nifurtimox and BenznidazoleAntimicrobial Agents and Chemotherapy, 2007
- Trypanothione-dependent glyoxalase I in Trypanosoma cruziBiochemical Journal, 2006